Compare Global E Online Ltd (GLBE) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global E Online Ltd vs Merck & Co., Inc. — how do they compare? Global E Online Ltd trades at $39.81 (market cap $6.54B), while Merck & Co., Inc. trades at $142.39 (market cap $352.29B). The key difference: Merck & Co., Inc. is far larger — about 53.9× Global E Online Ltd's market cap, and Merck & Co., Inc. pays a 2.38% dividend while Global E Online Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global E Online Ltd for 21 Days and Merck & Co., Inc. for 98 Days on average.
| GLBE | MRK | |
|---|---|---|
Market Cap | $6.54B | $352.29B |
Volume | 1,011,873 | 6,348,796 |
Sector | Consumer Cyclical | Health |
52-Week High | $42.36 | $156.43 |
52-Week Low | $27.54 | $82.49 |
Typical Hold Time | 21 Days | 98 Days |
Enterprise Value | $6.04B | $399.05B |
Dividend Yield | — | 2.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GLBE trades at $38.96, up 0.67% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings, beating EPS estimates, and raised its full-year outlook, with revenue growth of 39% year-over-year. Recent news includes the appointment of Tomer Gold as Chief Revenue Officer and significant insider selling by executives.
The outlook is positive with robust analyst support—93% buy ratings and a $48.86 consensus price target implying 25% upside. Key risks include insider selling pressure and execution challenges in maintaining high growth. Earnings growth and margin expansion remain primary catalysts for stock appreciation.
Merck (MRK) trades at $142.40, up 0.33% on the day, with a bearish technical signal but strong analyst support. The company reported revenue of $65.0B in 2025 with a net income margin of 28.07%, though 2026 projections show a sharp decline to 4.76%. Recent acquisition activity includes the tender offer for Terns Pharmaceuticals to bolster its oncology pipeline, while cash flow trends indicate significant investing outflows in 2026.
The outlook is mixed: robust fundamentals and a consensus price target of $159.59 suggest upside, but high valuation ratios (P/E 114.23) and projected earnings volatility pose risks. Investors should weigh strong institutional buying against technical weakness and competitive pressures in the pharma sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global E Online Ltd
Global-e provides a platform for cross-border e-commerce, helping retailers increase international sales by localizing the shopping experience for consumers in over 200 destinations worldwide.
Read more on GLBE →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
